Advanced ligand-based virtual screening software to dramatically increase your wet screening hit rate at a fraction of the cost
Virtual screening software platform, Blaze™ uses the 3D electrostatics and shape of a defined ligand to rapidly search large chemical collections for molecules with similar properties. By adjusting the level of influence played by each of these factors, users can achieve a high diversity of hits, with hit rates as high as 30%.
With a virtual screen of 10 million structures taking just a few hours, Blaze enables huge time and cost savings. It reduces the need to purchase chemical compounds and load them into lab apparatus. Users can simply hand over the best quality leads to the lab, making early-stage drug development more cost-effective, and reducing the environmental impact caused by wasted chemicals.
Use Blaze to find alternatives to typically problematic drug types. Reduce side effects, counteract resistance, and improve short-term efficacy by replacing steroids with non-steroids. Counteract poor oral bioavailability, rapid degradation, and the need for frequent dosing, all commonly associated with peptide drugs, by replacing them with non-peptides.
The prospect of running a virtual screen of 10 million compounds may sound like a significant computational expense. Thanks to our virtual screening web server, Blaze Cloud, we can offer a fast and flexible solution to those lacking internal computing power.
Available on a per-project basis, millions of commercially available compounds can be searched using a secure, encrypted web browser session.
We sought the scientific expertise within the Cresset Discovery Services team to utilize their novel field and shape-based virtual screening methods in Blaze™, and their proprietary Electrostatic Complementarity™ technique to help identify a backup series for our target effectively and efficiently. Ultimately we identified 9 novel chemotypes that were clearly distinct to those arising from docking and pharmacophore virtual screening approaches, which was an exciting outcome for us.
Dr Zara Sands, Head of CADD and Informatics, Confo Therapeutics, Belgium
Flare gives us an excellent assessment of the potential binding of hits. We use it to triage hits from Blaze and Forge experiments in the absence of 3D-QSAR, narrowing them down to an affordable subset of the most promising hits.
Dr Graeme Stevenson, Cancer Therapeutics CRC, Australia
This is a very important and exciting project for my team so thank you for your good work. The incredibly high hit rate from the Blaze compound list is intriguing.